Blood Test Predicts Alzheimer's Risk 5 Years Early

A blood test can now tell cognitively healthy people if they're likely to develop Alzheimer's disease within the next five years, giving them precious time to take action before symptoms appear.

Researchers from Mass General Brigham studied nearly 2,700 older adults across three continents over two decades. They discovered that measuring a biomarker called p-tau217 in blood samples accurately predicted who would develop cognitive problems down the road.

The results are striking. People with very high p-tau217 levels had a 38% chance of developing cognitive impairment within five years and a 78% chance within ten years, even when they felt completely fine at the time of testing.

What makes this test truly revolutionary is its independence. The prediction held true regardless of brain scans showing amyloid plaques or whether someone carried high-risk genetic variants like APOE4.

Dr. Reisa Sperling, who led the study, emphasizes that the test isn't yet recommended for routine screening because approved treatments for pre-symptomatic Alzheimer's don't currently exist. For now, anyone with high-risk results would receive the same advice doctors already give: exercise regularly, eat well, prioritize sleep, and maintain overall wellness.

But the landscape is changing fast. Multiple clinical trials are testing disease-modifying therapies that might prevent Alzheimer's before it starts, and this blood test provides the perfect tool to identify ideal candidates for these studies.

The test recently received federal clearance, and its immediate application lies in accelerating research. Scientists can now quickly and affordably screen thousands of people to find those at highest risk, then test whether preventive treatments work when the brain is still healthy enough to protect.

Why This Inspires

This breakthrough represents a fundamental shift in how we might approach brain health. Just as cholesterol tests revolutionized heart disease prevention by identifying at-risk individuals decades before a heart attack, p-tau217 testing could give people years of advance warning about Alzheimer's risk.

The research team's long-term vision mirrors cardiovascular care: accessible screening that guides proactive monitoring and early intervention before devastating symptoms emerge. Instead of diagnosing Alzheimer's after memory loss begins, doctors could help patients preserve their cognitive health while they're still thriving.

For the 478 study participants who developed cognitive impairment, earlier knowledge might have meant more time to strengthen their health, participate in cutting-edge trials, or simply prepare while still able to make meaningful decisions.

The future Dr. Sperling envisions is one where a simple blood draw during your annual checkup reveals your brain health trajectory, empowering you to take action when it matters most.